Posted on 06/02/2009 in Pharmaceutical Company Product News Boehringer Ingelheim and Cenix have signed a research deal, it has been revealed.
The collaboration will see study and support provided by the latter to the former in discovering novel drug targets.
Cenix noted it will combine high throughput applications of RNAi-based gene silencing, along with high content phenotypic analyses using cultured human cells.
The company added its multi-parametric microscopy-based assays will be used to complement proprietary types of the measuring method, which are developed by Boehringer Ingelheim.
Dr Christophe Echeverri, chief executive and scientific officer of Cenix, said the organisation had "long been looking forward" to the deal with its partner.
He noted: "We expect that the excellent complementarities between the two teams will deliver a particularly productive and cost-effective driver for these programmes."
In December last year, Boehringer Ingelheim announced a collaboration agreement with Derdack.
Under the terms of the agreement, the former will use the latter's message master Enterprise Alert system.Other news stories from 06/02/2009
Read more in the Zenopa News Archive
How this news is generated
|
